Graft-versus-host disease

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 131-138

  Marcellus, Deborah C ^a   Vogelsang, Georgia B ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; STEROID; TACROLIMUS; THALIDOMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0030914405     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00005     Document Type: Review

References (41)

1. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JHF, Vossen J, Gratwohl A, Vogelsang GB, Van Houwelingen HC, van Rood JJ: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996, 334:281-285. This paper reports on the association of acute GVHD and minor antigen mismatches. This is one of two papers proving that minor antigenic differences are important in human GVHD.
2. Behar E, Chao NJ, Hiraki DD, Krishnaswamy S, Brown BW, Zehnder JL, Grumet FC: Polymorphism of adhesion molecule CD31 and it's role in acute graft-versus-host disease. N Engl J Med 1996, 334:286-291. The adhesion molecule CD31 has been found to be a minor antigen. Disparity in donor-recipient genotypes is associated with higher rates of GVHD.
3. Liu X, Chesnokova V, Forman SJ, Diamond DJ: Molecular analysis of T-cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T-cell expansion in graft-versus-host disease lesions. Blood 1996, 87:3032-3044.
4. Kubo K, Yamanaka K, Kiyoi H, Fukutani H, Ito M, Hayakawa R, Ohno R, Naoe T: Different T-cell receptor repertoires between lesions and peripheral blood in acute graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1996, 87:3019-3026.
5. Gaschet J, Trevino MA, Cherel M, Vivien R, Garcia-Sahuquillo A, Hallen MM, Bonneville M, Harrousseau JL. Bragado R, Milpied N, Vie H: HLA-target antigens and T-cell receptor diversity of activated T-cells invading the skin during acute graft-versus-host disease. Blood 1996, 87:2345-2353. Clones from patients receiving one antigen mismatch transplant were documented to be directed against the mismatched HLA antigen. This suggests that HLA targets are indeed early targets in GVHD.
6. Schultz KR, Bader S, Paquet J, Li W: Chloroquine treatment affects T- cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood 1995, 86:4344-4352. Chloroquine prevents presentation of antigen in vitro by affecting invariant chain dissociation from MHC class II. Treatment of mice receiving minor mismatched transplants prevents GVHD.
7. Pan L, Delmonte J, Jalonen CK, Ferrara JLM: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86:4422-4429. In this very important paper, the authors demonstrated that the T cells recruited by G-CSF during peripheral blood mobilization are mainly type 2 helper cells. This explains the low rate of acute GVHD after peripheral blood transplants.
8. Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM: Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996, 87:4887-4893.
9. 2-ricin toxin A chain immunotoxin. Blood 1995, 86:4367-4375.
10. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ: FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996, 87:3514-3519. Of clinical interest, this phase II multicenter study demonstrates FK506 monotherapy has activity in preventing GVHD and warrants further investigation at lower doses to improve tolerability.
11. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, Kempeni J, Wilmanns W: Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 1995, 86:890-899. This paper presents interesting data regarding the role of conditioning regimen-related, cytokine release in the induction of early acute GVHD.
12. Heslop HE, Benaim E, Brenner MK, Krance RA, Stricklin LM, Rochester RJ, Billing R: Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet 1995, 346:805-806.
13. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation (second of two parts). N Engl J Med 1975, 292:895-902.
14. Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, di Bartolomeo P, Boogaerts M, Bosi A, Carreras E, Devergie A, Ferrant A, Fibbe WE, Frassoni F, Gahrton G, Goldman J, Iriondo A, Jacobsen N, Kolb HJ, Link H, Michallet M, Prentice HG, Reiffers J, Rhee FV, Ruutu T, Schwaighofer H, Vernant JP, de Witte T, Niederwieser D: Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995, 86:813-818.
15. Kalhs P, Schwarzinger I, Anderson G, Mori M, Clift RA, Storb R, Buckner CD, Appelbaum FR, Hansen JA, Sullivan KM: A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86:2028-2032.
16. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molino A, Stepan DE, Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K, Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC, Blume KG, Forman SJ: Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995, 86:3604-3609. Results of thalidomide in the treatment of 86 patients with chronic GVHD are added to previously reported experience with this agent. These authors found that a high incidence of reversible side effects limited dose intensity and ultimately the number of patients who could benefit from this therapy.
17. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992, 326:1055-1058.
18. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995, 86:2842-2848.
19. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T. Loffler H, Hunter A, Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672. This clinical experience using G-CSF-mobilized peripheral blood progenitor cells for allogeneic BMT in eight patients suggest that this is feasible and not associated with detrimental GVHD.
20. Rosenfeld C, Collins R, Pineiro L, Agura E, Nemunaitis J: Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study. J Clin Oncol 1996, 14:1314-1319. This report of results in 19 patients further supports the feasibility of using G-CSF-mobilized peripheral blood progenitor cells as an alternative to bone marrow for allogeneic BMT.
21. + selected peripheral blood cell product, the rate of acute GVHD among 10 patients was higher in this report than that seen with unmanipulated PBSC products used by the two previous authors.
22. Matsunaga T, Sakamaki S, Kohgo Y, Ohi S, Hirayama Y, Niitsu Y: Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993, 11:103-108.
23. Weaver CH, Buckner CD, Longin K, Appelbaum FR, Rowley S, Lilleby K, Miser J, Storb R, Hansen JA, Bensinger W: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993, 82:1981-1984.
24. Fritsch G, Fischmeister G, Haas OA, Peters C, Gadner H, Strobl H, Hocker P, Kurz M: Peripheral blood hematopoietic progenitor cells of cytokine-stimulated healthy donors as an alternative for allogeneic transplantation [letter]. Blood 1994, 83:3420-3421.
25. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994, 84:2795-2801.
26. Kolb HJ, Mittermuller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
27. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993, 82:2310-2318.
28. Porter DL, Roth MS, McGarigle C, Ferrera JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994, 330:100-106.
29. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993, 12:125-129.
30. Bar BMAM, Schattenberg A, Mensink EJBM, Geurts Van Kessel A, Smetsers TFCM, Knops GHJN, Linders EHP, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993, 11:513-519.
31. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268. This paper presents provocative data regarding the dose of donor leukocytes or T-cells required to produce a GVL effect but further work in this area is required. It is clear from this study, however, that in some patients, the GVL effect can occur in the absence of clinical GVHD.
32. Davies SM, Shu XO, Blazar BR, Filipovich AH, Kersey JH, Krivit W, McCullough J, Miller WJ, Ramsay NKC, Segall M, Wagner JE, Weisdorf DJ, McGlave PB: Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995, 86:1636-1642. Outcomes of 211 consecutive unrelated BMTs are presented. The authors concluded that unrelated BMT with a major mismatch at one HLA-A or -B locus is well tolerated in young, but not in older, recipients.
33. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995, 86:1606-1613. Based on their findings in 364 patients, these authors suggest that prospective matching of patients and donors for DRB1 alleles is warranted.
34. Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, O'Donnell M, Smith EP, Stepan DE, Molina A, Wong KK, Margolin K, Somlo G, Littrell B, Woo D, Sniecinski I, Niland JC, Forman SJ: The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995, 86:1228-1234. These authors provide additional data to support the use of molecular as well as serologic typing of unrelated donor-recipient pairs.
35. Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf EW, Appelbaum FR, Buckner CD, Matthews D, Storb R, Sullivan KM, Hansen JA: Unrelated donor marrow transplantation in children. Blood 1995, 86:3247-3256. This report indicates that both fully and partially HLA-matched unrelated donors may be effectively used in children with disease status and the occurrence of GVHD remaining important factors in determining outcome.
36. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, Henslee-Downey J, Trigg ME, Cowan MJ, Sanders J, Bunin N, Weinstein H, Lenarsky C, Falk P, Harris R, Bowen T, Williams TE, Grayson GH, Warkentin P, Sender L, Cool VA, Crittenden M, Packman S, Kaplan P, Lockman LA, Anderson J, Krivit W, Dusenbery K, Wagner J: Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996, 87:4894-4902.
37. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA. Roth M, Flomenberg N, Drobyski WR: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86:3987-3996. In chronic phase CML patients, relapse rates were lower among those receiving T-cell-depleted marrow from unrelated donors than in those receiving T-cell-depleted marrow from their HLA-identical siblings. The authors suggest that some but not all of the enhanced GVL effect was GVHD related. No difference in relapse was seen among patients with more advance disease.
38. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM: Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995, 86:3590-3597. Among 115 patients with CML, T-cell depleted unrelated BMT appeared to be a reasonable option for those in chronic phase, with low rates of acute and chronic GVHD as well as relapse.
39. Beatty PG, Mori M, Milford E: Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995, 60:778-783. Even with increased representation of racial minorities in unrelated donor registries, genetic polymorphism among races may limit successful identification of an HLA-matched unrelated donor.
40. Schipper RF, D'Amara J, Oudshoorn M: The probability of finding a suitable related donor for bone marrow transplantation in extended families. Blood 1996, 87:800-804.
41. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166. HLA-mismatched placental blood from unrelated donors may be an alternative to bone marrow as a source of reconstituting hematopoietic progenitor cells.